eNauka - pregled
Pregled prema Autor Chawla, T
Prikaz rezultata 1 do 3 od 3
| Godina | Naslov | Autor(i) | Tip rezultata | Mp-kat. |
|---|---|---|---|---|
| 2022 | HERIZON overall survival results: A study of IMU-131, a HER2 targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2 overexpressing metastatic or advanced gastric/GEJ cancer | Maglakelidze, Marina; Ryspayeva, D; Andric, Zoran G   ; Petrovic, Zeljko M; Bulat, IV; Nikolic, Ivan V ; Chawla, T; Nagarkar, R; Wiedermann, Ursula; Blumenstein, BA;
Chong, LMO; Ede, NJ; Nixon, B; Good, AJ;
| Konferencijski rad | Mp kategorija će biti prikazana naknadno. |
| 2023 | HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2t-argeting peptide vaccine plus SOC chemotherapy in patients with HER2+advanced stomach cancer - correlation of the antibody responses and clinical outcome | Tobias, Joshua; Kundi, Michael; Garner-Spitzer, E; Zielinski, Christoph; Maglakelidze, Marina; Andric, Zoran G ; Petrovic, Zeljko M; Nagarkar, R; Chawla, T; Chong, LMO;
Nixon, B; Yavrom, S; Ede, NJ; Wiedermann, Ursula;
| Konferencijski rad | Mp kategorija će biti prikazana naknadno. |
| 2023 | HERIZON: A phase II study of HER-Vaxx (IMU-131), a HER2targeting peptide vaccine plus standard of care chemotherapy in patients with HER2+advanced stomach cancer - Dose-dependent anti-cancer antibodies correlating with improved clinical outcome | Tobias, Joshua; Kundi, Michael; Garner-Spitzer, E; Zielinski, Christoph; Maglakelidze, Marina; Andric, Zoran G ; Petrovic, Z; Nagarkar, R; Chawla, T; Chong, LO;
Nixon, B; Yavrom, S; Ede, NJ; Wiedermann, Ursula;
| Konferencijski rad | Mp kategorija će biti prikazana naknadno. |